The estimated Net Worth of Capital, Llc Casdin Partner... is at least 20.8 百万$ dollars as of 23 July 2018. Capital Partner owns over 266,667 units of Constellation Pharmaceuticals Inc stock worth over 20,817,176$ and over the last 6 years Capital sold CNST stock worth over 0$.
Capital has made over 1 trades of the Constellation Pharmaceuticals Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently Capital bought 266,667 units of CNST stock worth 4,000,005$ on 23 July 2018.
The largest trade Capital's ever made was buying 266,667 units of Constellation Pharmaceuticals Inc stock on 23 July 2018 worth over 4,000,005$. On average, Capital trades about 266,667 units every 0 days since 2018. As of 23 July 2018 Capital still owns at least 612,450 units of Constellation Pharmaceuticals Inc stock.
You can see the complete history of Capital Partner stock trades at the bottom of the page.
Capital's mailing address filed with the SEC is 6th Ave, New York, NY, USA.
Over the last 15 years, insiders at Constellation Pharmaceuticals Inc have traded over 36,293,867$ worth of Constellation Pharmaceuticals Inc stock and bought 6,651,976 units worth 88,473,679$ . The most active insiders traders include Peter Svennilson、Of The University Of Califo...、Anthony B Evnin. On average, Constellation Pharmaceuticals Inc executives and independent directors trade stock every 17 days with the average trade being worth of 4,934,940$. The most recent stock trade was executed by Mark A Goldsmith on 4 March 2021, trading 14,987 units of CNST stock currently worth 509,408$.
Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapeutics that selectively modulate gene expression to address serious unmet medical needs in patients with cancer. The Company has a deep understanding of how epigenetic and chromatin modifications in cancer cells and in the tumor and immune microenvironment play a fundamental role in driving disease progression and drug resistance. Constellation is driving development of the BET inhibitor CPI-0610 for the treatment of myelofibrosis as well as the EZH2 inhibitor CPI-0209 for the treatment of solid tumors. The Company is also applying its broad research and development capabilities to explore other novel targets that directly and indirectly impact gene expression to fuel a sustainable pipeline of innovative small-molecule product candidates.
Constellation Pharmaceuticals Inc executives and other stock owners filed with the SEC include: